

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10522497	
	Filing Date		2005-09-07	
	First Named Inventor	Philippe Bernard		
	Art Unit	1624		
	Examiner Name	Not Yet Assigned		
	Attorney Docket Number	REGIM 3.3-048		

U.S.PATENTS							Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1	3910907		1975-10-07	O'Brien et al.			
	2	3995039		1976-11-30	Rooney et al.			
	3	4183930		1980-01-15	Cohen et al.			
If you wish to add additional U.S. Patent citation information please click the Add button.							Add	
U.S.PATENT APPLICATION PUBLICATIONS							Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1							
If you wish to add additional U.S. Published Application citation information please click the Add button.							Add	
FOREIGN PATENT DOCUMENTS							Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² i	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	269859	EP		1988-06-08	Otsuka Pharma Co Ltd		<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10522497
Filing Date		2005-09-07
First Named Inventor	Philippe Bernard	
Art Unit		1624
Examiner Name	Not Yet Assigned	
Attorney Docket Number		REGIM 3.3-048

	2	1515107	EP		2005-03-16	Lg Electronics Inc		<input type="checkbox"/>
	3	2230366	FR		1974-12-20	Sandoz Sa		<input type="checkbox"/>
	4	2818278	FR		2002-06-21	Sod Conseils Rech Applic		<input checked="" type="checkbox"/>
	5	00/59907	WO		2000-10-12	Du Pont Pharm Co		<input type="checkbox"/>
	6	01/23388	WO		2001-04-05	Neurogen Corp et al.		<input type="checkbox"/>
	7	02/50079	WO		2002-06-27	SOD CONSEILS RECH APPLIC		<input type="checkbox"/>
	8	02/72202	WO		2002-09-19	Bristol Myers Squibb Pharma Co		<input type="checkbox"/>
	9	98/03510	WO		1998-01-29	Du Pont Merck Pharma		<input type="checkbox"/>
	10	99/38868	WO		1999-08-05	Du Pont Pharm Co		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

Add

NON-PATENT LITERATURE DOCUMENTS

Remove

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
-----------------------	------------	---	----------------

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10522497
Filing Date	2005-09-07
First Named Inventor	Philippe Bernard
Art Unit	1624
Examiner Name	Not Yet Assigned
Attorney Docket Number	REGIM 3.3-048

1	Ballard, A.S., Gingell, C.J., Tang, K., Turner, L.A., PRICE, M.E. (J. Urol, 1998, 159, 2164-2171)	<input type="checkbox"/>
2	Estevez A.G. et al. (J. Neurosci. 1998, 18(3), 923-931)	<input type="checkbox"/>
3	Rathbone, M.P. et al. Prog. Neurobiol. (1999), 59, 663-690)	<input type="checkbox"/>
4	Sanga et al, J. Med. Chem. 1982, 25, 243-249	<input type="checkbox"/>
5	Schindler, R., Mancilla, J., Endres, S., Ghorbani, R., Clark, S.C. and Dinarello, C.A. (Blood, 1990, 75, 40-47)	<input type="checkbox"/>
6	Torphy, T.J., Zhou, H.L. and Cieslinski, L.B. (J. Pharmacol. Exp. Ther., 1992, 263, 1195-1205)	<input type="checkbox"/>
7	Weishaar, R.E., Burrows, S.D., Kobylarz, D.C., Quade, M.M. and Evans, D.B. (Biochem. Pharmacol., 1986, 35, 787-800)	<input type="checkbox"/>
8	Perez-Torres, S. et al., J. Chem. Neuroanatomy, 2000, 20, 349-374)	<input type="checkbox"/>
9	ROBINS R K ET AL: "PURINE ANALOG INHIBITORS OF XANTHINE OXIDASE - STRUCTURE ACTIVITY RELATIONSHIPS AND PROPOSED BINDING OF THE MOLYBDENUM COFACTOR" JOURNAL OF HETEROCYCLIC CHEMISTRY, HETEROCORPORATION. PROVO, US, vol 22, 1 May 1985 (1985-05-01) , pages 601-634.	<input type="checkbox"/>
10	RABOISSON, PIERRE ET AL: "A General Approach toward the Synthesis of C-Nucleoside Pyrazolo[1,5-a]-1,3,5-triazines and Their 3' ,5'-Bisphosphate O-Nucleotide Analogues as the First Reported in Vivo Stable P2Y1-Receptor Antagonists" JOURNAL OF ORGANIC CHEMISTRY (2002), 67(23), 8063-8071	<input type="checkbox"/>
11	Nicholson C.D., JACKMAN S.A. and WILKE R. (Brit. J. Pharmacol. 1989, 97, 889-897)	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10522497
Filing Date		2005-09-07
First Named Inventor	Philippe Bernard	
Art Unit	1624	
Examiner Name	Not Yet Assigned	
Attorney Docket Number	REGIM 3.3-048	

	12	Cassina P. et al. (J. Neurosci. Res. 2002 67(1): 21-9)	<input type="checkbox"/>
--	----	--	--------------------------

If you wish to add additional non-patent literature document citation information please click the Add button

Add

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.